Anavex Life Sciences Corp. (NASDAQ: AVXL) announced results from a preclinical study of blarcamesine in a Parkinson's disease model at the AD/PD 2026 Conference. The study examined the drug's effects in a model combining alpha-synuclein pathology and noradrenergic degeneration.

According to the company, blarcamesine treatment for six weeks showed effects on motor function and dopaminergic nerve fiber density in the striatum. The model was designed to mimic aspects of Parkinson's disease pathology through protein buildup and nerve degeneration.

"It was quite important to demonstrate that blarcamesine can improve motor function and stimulate the growth of dopaminergic nerve fibers even after the establishment of alpha-synuclein pathology, in a clinically relevant dual-hit preclinical model of Parkinson´s disease," said Angela Cenci Nilsson, a professor at Lund University, Sweden.

Christopher Missling, Anavex's president and chief executive officer, stated that the results support the company's decision to advance clinical development of blarcamesine in early Parkinson's disease. The company has previously completed Phase 2 studies of the drug in Parkinson's disease dementia.

Blarcamesine is an oral drug candidate that targets SIGMAR1 and muscarinic receptors. The company has conducted clinical trials of the drug in Alzheimer's disease and Rett syndrome. The Michael J. Fox Foundation for Parkinson's Research previously provided funding for preclinical development of the drug for Parkinson's disease treatment.

The study information is based on a company press release announcing the conference presentation.